Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Receives Consensus Rating of “Buy” from Brokerages

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has been given an average rating of “Buy” by the seven analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $115.67.

Several analysts have recently weighed in on ENTA shares. Berenberg Bank set a $130.00 price objective on shares of Enanta Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, September 18th. Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 12th. BidaskClub raised shares of Enanta Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, ValuEngine raised shares of Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday.

Shares of Enanta Pharmaceuticals stock traded down $0.09 on Thursday, hitting $71.82. 190,200 shares of the company traded hands, compared to its average volume of 214,879. The firm’s 50-day simple moving average is $70.54 and its 200 day simple moving average is $84.65. The company has a market cap of $1.41 billion, a P/E ratio of 20.64 and a beta of 0.97. Enanta Pharmaceuticals has a 12-month low of $63.37 and a 12-month high of $106.80.



Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.27. The firm had revenue of $44.40 million for the quarter, compared to analysts’ expectations of $46.98 million. Enanta Pharmaceuticals had a net margin of 29.22% and a return on equity of 15.16%. The business’s quarterly revenue was down 22.5% on a year-over-year basis. During the same quarter last year, the company posted $0.97 EPS. Research analysts forecast that Enanta Pharmaceuticals will post 2.47 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in ENTA. Point72 Asset Management L.P. bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at $34,000. Bank of Montreal Can grew its holdings in Enanta Pharmaceuticals by 198.3% in the 2nd quarter. Bank of Montreal Can now owns 2,300 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 1,529 shares during the last quarter. Jane Street Group LLC bought a new stake in Enanta Pharmaceuticals in the 2nd quarter worth $208,000. GAM Holding AG bought a new stake in Enanta Pharmaceuticals in the 2nd quarter worth $215,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Enanta Pharmaceuticals in the 2nd quarter worth $224,000. 88.57% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Read More: What is the definition of arbitrage?

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.